PTPN2/PTPN1 inhibition enhances ex vivo T- cell responses and potentiates mosunetuzumab activity in chronic lymphocytic leukemia
BackgroundChronic lymphocytic leukemia (CLL) is characterized by T-cell dysfunction that limits the efficacy of immunotherapies, including CD20×CD3 bispecific antibodies. Protein tyrosine phosphatases non-receptor type 2/1 PTPN2/PTPN1 are central intra…